| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | BIOSTRATEGIES LC | 504 UNIVERSITY LOOP W | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43NS127662 | Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS | 000 | 1 | NIH | 10/22/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,498,067 ) |
| | 2024 | 2024 | BIOSTRATEGIES LC | 504 UNIVERSITY LOOP W | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS134453 | Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome) | 000 | 2 | NIH | 8/8/2024 | $1,498,067 |
| | 2024 | 2024 | BIOSTRATEGIES LC | 504 UNIVERSITY LOOP W | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS134453 | Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome) | 001 | 2 | NIH | 8/26/2024 | $0 |
| | 2024 | 2021 | BIOSTRATEGIES LC | 504 UNIVERSITY LOOP W | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44HD087099 | Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | 000 | 3 | NIH | 7/29/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,615,736 ) |
| | 2023 | 2023 | BIOSTRATAGIES LC | 504 UNIVERSITY LOOP E | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43HD114328 | Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases | 000 | 1 | NIH | 9/20/2023 | $295,923 |
| | 2023 | 2023 | BIOSTRATAGIES LC | 504 UNIVERSITY LOOP E | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS134453 | Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome) | 001 | 1 | NIH | 9/25/2023 | -$1,500,000 |
| | 2023 | 2023 | BIOSTRATAGIES LC | 504 UNIVERSITY LOOP E | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS134453 | Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome) | 001 | 1 | NIH | 9/25/2023 | $1,500,000 |
| | 2023 | 2023 | BIOSTRATAGIES LC | 504 UNIVERSITY LOOP E | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS134453 | Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome) | 000 | 1 | NIH | 9/15/2023 | $1,500,000 |
| | 2023 | 2023 | BIOSTRATAGIES LC | 504 UNIVERSITY LOOP E | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43HD114328 | Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases | 001 | 1 | NIH | 9/29/2023 | $0 |
| | 2023 | 2021 | BIOSTRATAGIES LC | 504 UNIVERSITY LOOP E | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44HD087099 | Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | 000 | 3 | NIH | 3/31/2023 | $0 |
| | 2023 | 2020 | BIOSTRATAGIES LC | 504 UNIVERSITY LOOP E | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43AR077353 | Treatment of muscular symptoms in Pompe rare disease via lectin assisted ERT delivery | 000 | 1 | NIH | 5/2/2023 | $0 |
| | 2023 | 2018 | BIOSTRATAGIES LC | 504 UNIVERSITY LOOP E | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS084565 | Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease | 000 | 3 | NIH | 6/20/2023 | -$180,187 |
| | 2023 | 2018 | BIOSTRATAGIES LC | 504 UNIVERSITY LOOP E | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS102086 | Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | 000 | 2 | NIH | 9/25/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $390,497 ) |
| | 2022 | 2022 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43NS127662 | Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS | 000 | 1 | NIH | 7/5/2022 | $390,497 |
| | 2022 | 2019 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43HL147752 | Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease | 000 | 1 | NIH | 12/20/2021 | $0 |
| | 2022 | 2018 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43AR073543 | MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme | 000 | 1 | NIH | 12/22/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $905,262 ) |
| | 2021 | 2021 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44HD087099 | Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | 000 | 3 | NIH | 3/26/2021 | $905,262 |
| | 2021 | 2018 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS084565 | Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease | 000 | 3 | NIH | 8/17/2021 | $0 |
| | 2021 | 2018 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS102086 | Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | 000 | 2 | NIH | 8/5/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,394,737 ) |
| | 2020 | 2020 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44HD087099 | Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | 000 | 2 | NIH | 4/8/2020 | $1,144,737 |
| | 2020 | 2020 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43AR077353 | Treatment of muscular symptoms in Pompe rare disease via lectin assisted ERT delivery | 000 | 1 | NIH | 8/11/2020 | $250,000 |
| | 2020 | 2018 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS084565 | Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease | 000 | 3 | NIH | 8/27/2020 | $0 |
| | 2020 | 2018 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43AR073543 | MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme | 000 | 1 | NIH | 6/30/2020 | $0 |
| | 2020 | 2018 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS102086 | Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | 000 | 2 | NIH | 8/20/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $293,232 ) |
| | 2019 | 2019 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43HL147752 | Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease | 000 | 1 | NIH | 8/29/2019 | $293,232 |
| | 2019 | 2016 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43HD087099 | Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | 000 | 1 | NIH | 11/23/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $2,443,904 ) |
| | 2018 | 2018 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43AR073543 | MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme | 000 | 1 | NIH | 6/12/2018 | $225,000 |
| | 2018 | 2018 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS102086 | Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | 000 | 2 | NIH | 7/19/2018 | $1,147,007 |
| | 2018 | 2018 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS084565 | Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease | 000 | 3 | NIH | 8/31/2018 | $1,071,897 |
| | 2018 | 2016 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS083230 | Enzyme replacement therapy for Sanfilippo A lysosomal rare disease | 000 | 3 | NIH | 6/14/2018 | $0 |
| | 2018 | 2015 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43NS086326 | Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | 000 | 2 | NIH | 12/14/2017 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $2,603,623 ) |
| | 2017 | 2017 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS102086 | Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | 000 | 1 | NIH | 9/25/2017 | $1,237,037 |
| | 2017 | 2017 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R44NS084565 | Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease | 000 | 2 | NIH | 9/8/2017 | $1,366,586 |
| | 2017 | 2014 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43AR066388 | Targeted Enzyme Replacement Therapy for Rare Forms of Osteogenesis Imperfecta | 000 | 1 | NIH | 11/1/2016 | $0 |
| | 2017 | 2014 | BIOSTRATAGIES, LC | 504 UNIVERSITY LOOP EAST | JONESBORO | AR | 72401 | CRAIGHEAD | USA | R43NS084565 | Enzyme Replacement Therapy for GM1 Gangliosidosis Lysosomal Rare Disease | 000 | 1 | NIH | 11/10/2016 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $884,425 ) |
| | 2016 | 2016 | BIOSTRATEGIES LC | POST OFFICE BOX 2428 | STATE UNIVERSITY | AR | 72467 | CRAIGHEAD | USA | R44NS083230 | Enzyme replacement therapy for Sanfilippo A lysosomal rare disease | 000 | 3 | NIH | 8/15/2016 | $659,425 |
| | 2016 | 2016 | BIOSTRATEGIES LC | POST OFFICE BOX 2428 | STATE UNIVERSITY | AR | 72467 | CRAIGHEAD | USA | R43HD087099 | Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | 000 | 1 | NIH | 7/5/2016 | $225,000 |
|
| Issue Date FY: 2015 ( Subtotal = $1,017,655 ) |
| | 2015 | 2015 | BIOSTRATEGIES LC | POST OFFICE BOX 2428 | STATE UNIVERSITY | AR | 72467 | CRAIGHEAD | USA | R43NS086326 | Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | 000 | 2 | NIH | 7/2/2015 | $185,915 |
| | 2015 | 2015 | BIOSTRATEGIES LC | POST OFFICE BOX 2428 | STATE UNIVERSITY | AR | 72467 | CRAIGHEAD | USA | R44NS083230 | Enzyme replacement therapy for Sanfilippo A lysosomal rare disease | 000 | 2 | NIH | 7/9/2015 | $831,740 |
|
|
